These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9511011)

  • 21. [Pharmacokinetics of baytril (enrofloxacin) in dogs].
    Küng K; Wanner M
    Schweiz Arch Tierheilkd; 1994; 136(10):329-34. PubMed ID: 7801085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Placental transfer of enrofloxacin and ciprofloxacin in rabbits.
    Aramayona JJ; Garcia MA; Fraile LJ; Abadía AR; Bregante MA
    Am J Vet Res; 1994 Sep; 55(9):1313-8. PubMed ID: 7802401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-bioequivalence of various trademarks of enrofloxacin and Baytril in cows.
    Sumano LH; Ocampo CL; Gutiérrez OL
    Dtsch Tierarztl Wochenschr; 2001 Jul; 108(7):311-4. PubMed ID: 11505850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative pharmacokinetic disposition of fluoroquinolones in the lung.
    Wise R; Baldwin DR; Andrews JM; Honeybourne D
    J Antimicrob Chemother; 1991 Dec; 28 Suppl C():65-71. PubMed ID: 1664831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apparent loss of enrofloxacin resistance in bovine Salmonella typhimurium strains isolated in Belgium, 1991 to 1998.
    Imberechts H; D'hooghe I; Bouchet H; Godard C; Pohl P
    Vet Rec; 2000 Jul; 147(3):76-7. PubMed ID: 10958489
    [No Abstract]   [Full Text] [Related]  

  • 26. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
    Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
    Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emergence of fluoroquinolone resistance in the native Campylobacter coli population of pigs exposed to enrofloxacin.
    Delsol AA; Sunderland J; Woodward MJ; Pumbwe L; Piddock LJ; Roe JM
    J Antimicrob Chemother; 2004 May; 53(5):872-4. PubMed ID: 15028665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The difluoroquinolone lomefloxacin--an broad spectrum antimicrobial drug].
    Padeĭskaia EN; Iakovlev VP
    Antibiot Khimioter; 1998; 43(2):30-9. PubMed ID: 9551171
    [No Abstract]   [Full Text] [Related]  

  • 29. Limited capacity of neonatal rabbits to eliminate enrofloxacin and ciprofloxacin.
    Fraile LJ; Martinez C; Aramayona JJ; Abadía AR; Bregante MA; García MA
    Vet Q; 1997 Nov; 19(4):162-7. PubMed ID: 9413113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and residues of enrofloxacin in chickens.
    Anadón A; Martínez-Larrañaga MR; Díaz MJ; Bringas P; Martínez MA; Fernàndez-Cruz ML; Fernández MC; Fernández R
    Am J Vet Res; 1995 Apr; 56(4):501-6. PubMed ID: 7785830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial activity, pharmacokinetics and clinical studies of balofloxacin (Q-35) in obstetrics and gynaecology.
    Cho N; Miyakawa Z; Kimura T; Shimizu A; Notake Y; Kunii K
    Drugs; 1995; 49 Suppl 2():391-2. PubMed ID: 8549373
    [No Abstract]   [Full Text] [Related]  

  • 32. Disposition of enrofloxacin and its metabolite ciprofloxacin after intramuscular injection in juvenile Burmese pythons (Python molurus bivittatus).
    Young LA; Schumacher J; Papich MG; Jacobson ER
    J Zoo Wildl Med; 1997 Mar; 28(1):71-9. PubMed ID: 9226619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two new fluoroquinolones.
    Med Lett Drugs Ther; 1992 Jun; 34(872):58-60. PubMed ID: 1317502
    [No Abstract]   [Full Text] [Related]  

  • 34. Campylobacter susceptibility to ciprofloxacin and corresponding fluoroquinolone concentrations within the gastrointestinal tracts of chickens.
    Farnell MB; Donoghue AM; Cole K; Reyes-Herrera I; Blore PJ; Donoghue DJ
    J Appl Microbiol; 2005; 99(5):1043-50. PubMed ID: 16238734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacodynamic and pharmacokinetic approaches to optimization of lomefloxacin].
    Iakovlev SV
    Antibiot Khimioter; 1998; 43(10):42-5. PubMed ID: 9825110
    [No Abstract]   [Full Text] [Related]  

  • 36. Sparfloxacin and other new fluoroquinolones.
    Richard P; Gutmann L
    J Antimicrob Chemother; 1992 Dec; 30(6):739-44. PubMed ID: 1337749
    [No Abstract]   [Full Text] [Related]  

  • 37. Penetration of enrofloxacin and ciprofloxacin into breast milk, and pharmacokinetics of the drugs in lactating rabbits and neonatal offspring.
    Aramayona JJ; Mora J; Fraile LJ; García MA; Abadía AR; Bregante MA
    Am J Vet Res; 1996 Apr; 57(4):547-53. PubMed ID: 8712523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Lomefloxacin hydrochloride (Maxaquin), a long-acting fluoroquinolone (information for specialists)].
    Kuznetsovoĭ SM
    Antibiot Khimioter; 1998; 43(2):40-1. PubMed ID: 9551172
    [No Abstract]   [Full Text] [Related]  

  • 39. Concentration of enrofloxacin in equine tissues after long-term oral administration.
    Giguère S; Bélanger M
    J Vet Pharmacol Ther; 1997 Oct; 20(5):402-4. PubMed ID: 9350262
    [No Abstract]   [Full Text] [Related]  

  • 40. Initial clinical experience with clinafloxacin in the treatment of serious infections.
    Tack KJ; McGuire NM; Eiseman IA
    Drugs; 1995; 49 Suppl 2():488-91. PubMed ID: 8549411
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.